SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~May 1431, ~~2018~~2019

APOTHECA BIOSCIENCES, INC.

(Exact name of registrant as specified in charter)

Nevada	000-55467	47-2055848
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

10901 Roosevelt Blvd, Suite 1000c

Saint Petersburg, Florida

33716

(Address of principal executive offices)

(Zip Code)

(~~720~~727) ~~370~~228-~~3554~~3994

Registrant’s telephone number

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 85.0102 -Departure ~~Other~~of ~~Events~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Agreements of Certain Officers.

~~December~~Effective ~~11,~~May ~~2018~~31, ~~the Company appeared for a publicized hearing which was held before the Sixth Circuit Court in Pinellas County~~2019, ~~Florida,~~Mr. ~~Judge~~Verghese ~~Jack~~has ~~Day~~resigned ~~presiding, for the purposes of obtaining a judicial declaratory judgment~~ as to the ~~Company’s~~Chief ~~status~~Technical ~~under~~Officer ~~the Securities laws for Rule 144 determination~~ and ~~other~~director ~~Securities~~of ~~matters, as to whether~~ the Company, ~~has~~Apotheca ~~ever~~Biosciences. The ~~been~~decision awas ~~“Shell”~~based ~~Company~~on ~~under~~personal ~~the~~matters ~~Securities~~not ~~Laws.~~related ~~Pursuant~~ to ~~Chapter~~any 86disagreement ofwith the ~~Florida Statutes, the~~ Company ~~had filed the declaratory action so the Court could determine whether the Company had ever met the definition of being a shell company under Rule 405 of the Securities Act~~. The Company ~~found~~is ~~this~~in ~~necessary~~the sofinal ~~that~~selection ~~all~~process ~~shareholders would be able to utilize Rule 144~~ for ~~exemption~~its ~~from~~Chief ~~registration,~~Science asOfficer ~~well~~which aswill ~~any~~replace ~~other use of~~ the ~~Shell~~Chief ~~definition~~Technical ~~under~~Officer ~~the Securities Act~~role.

At the hearing, the Court received evidence including corporate history, financials, SEC filings, other historical evidence, as well as relevant testimony. The Court entered an Order in the matter finding that the Company was not currently, nor had it ever been, a “Shell” company under the definition set forth under Rule 405, of the Securities Act; as well as for purposes of application of Rule 144 exemption from registration, and for any other application of the Shell definition under the Securities Act.SIGNATURES

~~The~~Pursuant ~~Order~~to the requirements of the ~~Court~~Securities asExchange ~~entered~~Act inof 1934, the ~~Sixth~~Registrant ~~Circuit~~has ~~Court~~duly ofcaused ~~Florida,~~this ~~Pinellas~~report ~~County~~to ~~under~~be ~~case~~signed ~~number~~on ~~2018-007747-CI~~its isbehalf ~~attached~~by asthe anundersigned ~~exhibit~~hereunto duly authorized.

Item 9.01 Financial Statements and Exhibits.

	APOTHECA BIOSCIENCES IN

Date: May 31, 2019	By:	/s/ P.C. Sundar
		P.C. Sundar, Chairman & CEO

(d) Exhibits

Exhibit No. Description

01 The Order of the Court as entered in the Sixth Circuit Court of Florida

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	APOTHECA BIOSCIENCES IN
Date: January 14, 2018	By:	/s/ John Verghese
		John Verghese Acting CEO

Filing Compare · Apotheca Biosciences, Inc.